2014
Nomogram for predicting overall and colostomy-free survival for patients with anal cancer.
Tsikitis V, Lu K, Kim J, Billingsley K, Thomas C, Herzig D. Nomogram for predicting overall and colostomy-free survival for patients with anal cancer. Journal Of Clinical Oncology 2014, 32: 400-400. DOI: 10.1200/jco.2014.32.3_suppl.400.Peer-Reviewed Original ResearchColostomy-free survivalNational Cancer DatabaseAnal cancerNodal statusTumor sizeStratified Cox proportional hazards modelCox proportional hazards modelPrimary end pointRadical surgical treatmentTNM clinical stageProportional hazards modelOutcome prediction toolLogistic regression modelsCancer ptsChemoradiotherapy approachSphincter preservationAbdominoperineal resectionFree survivalSurgical treatmentSurgery statusClinical stageTNM stageCancer DatabaseHazards modelEnd point
2011
S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma
Leichman L, Goldman B, Bohanes P, Lenz H, Thomas C, Billingsley K, Corless C, Iqbal S, Gold P, Benedetti J, Danenberg K, Blanke C. S0356: A Phase II Clinical and Prospective Molecular Trial With Oxaliplatin, Fluorouracil, and External-Beam Radiation Therapy Before Surgery for Patients With Esophageal Adenocarcinoma. Journal Of Clinical Oncology 2011, 29: 4555-4560. PMID: 22025151, PMCID: PMC3236655, DOI: 10.1200/jco.2011.36.7490.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDisease-Free SurvivalDrug Administration ScheduleEsophageal NeoplasmsEsophagectomyFemaleFluorouracilHumansMaleMiddle AgedNeoadjuvant TherapyOrganoplatinum CompoundsOxaliplatinRadiotherapy, AdjuvantConceptsPathologic complete responseEsophageal adenocarcinomaOverall survivalNeoadjuvant therapyExternal beam radiation therapyPhase II ClinicalProspective exploratory analysisPatient underwent surgeryPrimary end pointProgression-free survivalSouthwest Oncology GroupAdvanced esophageal adenocarcinomaSingle-arm trialGy/dNeoadjuvant oxaliplatinSystemic regimenPreoperative therapyR0 resectionUnderwent surgeryOncology GroupPCR rateComplete responseImproved survivalFuture trialsGrade 3